6. Conclusion

Apabetalone has a dual anti-viral and anti-inflammatory mechanism (Fig. 7) that positions it as a “variant-independent COVID therapeutic” with the potential to counter short- and long-term pathologic consequences caused by SARS-CoV-2 and variants of concern. The safety and efficacy of apabetalone to mitigate serious outcomes in high risk COVID-19 outpatients will be further assessed in an upcoming clinical trial. The ability of apabetalone to alleviate post-COVID syndrome associated with deleterious inflammatory responses will be the subject of future clinical evaluation.

Can someone clarify the last two statements, please?   Is this just very outdated info?  I thought that the "upcoming" FDA trial was for long-covid and not Covid-19 outpatients.  Anyone?